event in Greece

A program licensed by the American Society of Clinical Oncology

September 21-22 2018 | Crown Plaza Hotel | Athens

scientific program

Organizers

with the scientific collaboration of

ΔΗΛΩΣΕΙΣ ΣΥΜΜΕΤΟΧΗΣ
ΣΤO info@scep.gr

CME - CPD credits

scientific program
Welcome and Chair Remarks
V. Georgoulias
11.30-12.00

Session 1: Breast Cancer
Chairpersons: D. Tryfonopoulos, M. Nikolaou
12.00-12.15
Presenter: S. Kokkali
- Abstract ID: 506
  Title: PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results
- Abstract ID: 500
  Title: Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial

12.15-12.30
Presenter: S. Peroukidis
- Abstract ID: LBA1
  Title: TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node negative breast cancer and an intermediate prognosis 21-gene recurrence score
- Abstract ID: 1000
  Title: Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC): Results from MONALEESA-3

12.30-12.45
Presenter: F. Stavridi
- Abstract ID: 104
  Title: Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracine containing chemotherapy in triple negative breast cancer (TNBC).
- Abstract ID: 1005
  Title: Everolimus (EVE) + Exemestane (EXE) vs EVE Alone or Capecitabine (CAP) for Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2-negative (HER2−) Advanced Breast Cancer (ABC): BOLERO-6, an Open-label Phase 2 Study

12.45-13.00
Presenter: E. Moirogiorgou
- Abstract ID: LBA1006
  Title: Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER

Welcome and Chair Remarks
V. Georgoulias
11.30-12.00

Session 1: Breast Cancer
Chairpersons: D. Tryfonopoulos, M. Nikolaou
12.00-12.15
Presenter: S. Kokkali
- Abstract ID: 506
  Title: PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results
- Abstract ID: 500
  Title: Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial

12.15-12.30
Presenter: S. Peroukidis
- Abstract ID: LBA1
  Title: TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node negative breast cancer and an intermediate prognosis 21-gene recurrence score
- Abstract ID: 1000
  Title: Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC): Results from MONALEESA-3

12.30-12.45
Presenter: F. Stavridi
- Abstract ID: 104
  Title: Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracine containing chemotherapy in triple negative breast cancer (TNBC).
- Abstract ID: 1005
  Title: Everolimus (EVE) + Exemestane (EXE) vs EVE Alone or Capecitabine (CAP) for Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2-negative (HER2−) Advanced Breast Cancer (ABC): BOLERO-6, an Open-label Phase 2 Study

12.45-13.00
Presenter: E. Moirogiorgou
- Abstract ID: LBA1006
  Title: Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER

Welcome and Chair Remarks
V. Georgoulias
11.30-12.00

Session 1: Breast Cancer
Chairpersons: D. Tryfonopoulos, M. Nikolaou
12.00-12.15
Presenter: S. Kokkali
- Abstract ID: 506
  Title: PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results
- Abstract ID: 500
  Title: Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial

12.15-12.30
Presenter: S. Peroukidis
- Abstract ID: LBA1
  Title: TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node negative breast cancer and an intermediate prognosis 21-gene recurrence score
- Abstract ID: 1000
  Title: Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC): Results from MONALEESA-3

12.30-12.45
Presenter: F. Stavridi
- Abstract ID: 104
  Title: Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracine containing chemotherapy in triple negative breast cancer (TNBC).
- Abstract ID: 1005
  Title: Everolimus (EVE) + Exemestane (EXE) vs EVE Alone or Capecitabine (CAP) for Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2-negative (HER2−) Advanced Breast Cancer (ABC): BOLERO-6, an Open-label Phase 2 Study

12.45-13.00
Presenter: E. Moirogiorgou
- Abstract ID: LBA1006
  Title: Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER
Session 4: Gastrointestinal (Colorectal) Cancer
Chairpersons: N. Ziras, P. Papakostas

Presenter: V. Michalaki
- Abstract ID: 3505
  Title: First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study

Abstract ID: 3500
Title: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Final results of PETACC-6

Presenter: N. Tsoukalas
- Abstract ID: 3501
  Title: Long-term results of the ADORE trial: adjuvant oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) versus 5-fluorouracil and leucovorin (FL) after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer

Abstract ID: LBA 3503
Title: A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7

Discussant: K. Koutsoukos

Coffee Break

16.30-16.50 Discussant: K. Koutsoukos

16.50-17.00 Discussion

17.00-17.30 Coffee Break

17.30-18.30 Session 4: Gastrointestinal (Non-Colorectal) Cancer
Chairpersons: N. Kentepozidis, O. Katopodis

Discussion

18.30-19.30 Session 5: Gastrointestinal (Non-Colorectal) Cancer
Chairpersons: N. Kentepozidis, O. Katopodis

Presenter: T. Bilidas
- Abstract ID: LBA4001
  Title: Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized controlled phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas

- Abstract ID: 4004
  Title: A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211)

18.45-19.00 Presenter: A. Ntokou
- Abstract ID: LBA4008
  Title: Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: Efficacy and safety in the phase III randomized factorial ASPECT trial

- Abstract ID: LBA4002
  Title: Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial

19.00 – 19.20 Discussant: A. Karampeazis

19.20 – 19.30 Discussion

Saturday, September 22nd, 2018

09.00-10.30 Session 6: Lung Cancer (1)
Chairpersons: P. Kosmidis, A. Koutsopoulos

Douglas W. Mason, MD
- Abstract ID: 8503
  Title: DREAM: A Phase II study of DuRvalumab with first line chEmotherApy in Mesothelioma: First Results

- Abstract ID: 8506
  Title: Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158

09.15-09.30 Presenter: K. Rapti
- Abstract ID: 8507
  Title: Efficacy and safety of rovalpituzumabtesirine in patients With DLL3-expressing, ≥ 3rd line small cell lung cancer: results from the Phase 2 TRINITY study
09.30-09.45 Presenter: Th. Tegos
  - Abstract ID: 9001
  Title: Nivolumab (nivo) + ipilimumab (ipi) vs chemotherapy as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC); additional endpoints from the randomized phase 3 CheckMate 227 study
  - Abstract ID: 9006
  Title: Phase III study comparing bevacizumab plus erlotinib in patients with untreated NSCLC harboring activating EGFR mutations. NEJ026

09.45-10.00 Presenter: E. Res
  - Abstract ID: 8502
  Title: Pragmatic Study of a Lymph Node (LN) Collection Kit for Non-Small Cell Lung Cancer (NSCLC) Resection.
  - Abstract ID: 105
  Title: Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%. Open-label, phase 3 KEYNOTE-042 study

10.00-10.20 Discussant: N. Katirtzoglou
10.20-10.30 Discussion

10.30-11.30 Session 7: Genitourinary Cancer (Prostate cancer)
Chairpersons: Ch. Kourousis, D. Matthaios

10.30-10.45 Presenter: F. Koinis
  - Abstract ID: 5000
  Title: A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG-13 trial
  - Abstract ID: 5001
  Title: Ga-PSMA11 PET/CT localizes recurrent prostate cancer with high accuracy: Preliminary results from a phase 2/3 prospective trial

10.45-11.00 Presenter: A. Koulouris
  - Abstract ID: 5003
  Title: Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized Phase II trial
  - Abstract ID: 5007
  Title: KEYNOTE-199: pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC)

11.00-11.20 Discussant: Z. Zafeiriou
11.20-11.30 Discussion
11.30-12.00 Coffee Break

12.00-13.15 Session 8: Development Therapeutics – Clinical Pharmacology / Tumor Biology
Chairpersons: F. Zagouri, F. Papageorgiou

12.00-12.15 Presenter: N. Volakakis
  - Abstract ID: 102
  Title: A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers
  - Abstract ID: 3000
  Title: ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers

12.15-12.30 Presenter: E. Kontopodis
  - Abstract ID: 3003
  Title: Durability of Response in ZUMA-1, the Pivotal Phase 2 Study of AxicabtageneCiloleucel (Axi-Cel) in Patients (Pts) With Refractory Large B Cell Lymphoma
  - Abstract ID: 3006
  Title: NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT

12.30-12.45 Presenter: K. Stouraiti
  - Abstract ID: 12000
  Title: Association of high tissue TMB and atezolizumab efficacy across multiple tumor types
  - Abstract ID: 12001
  Title: Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results

12.45-13.05 Discussant: C. Emmanouilides
13.05-13.15 Discussion
13.15-14.15  **Light lunch**

14.15-15.15  **Session 9: Head and Neck Cancer**
Chairpersons: Ch. Panopoulos, D. Moraitis
Presenter: A. Tzovaras

14.15-14.30 - **Abstract ID: 6000**
Title: Results of a randomized phase III study of Nimotuzumab in combination with concurrent radiotherapy and Cisplatin versus radiotherapy and Cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck

14.30-14.45  **Presenter 2: P. Katsaounis**

- **Abstract ID: 6008**
Title: Multicenter Phase II Trial of Palbociclib, a Selective Cyclin Dependent Kinase (CDK) 4/6 Inhibitor, and Cetuximab in Platinum-Resistant HPV Unrelated (-) Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)

- **Abstract ID: 6009**
Title: A phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC)

14.45-15.05  **Discussant: A. Argiris**

15.05-15.15  **Discussion**

15.15-16.15  **Session 10: Sarcomas**
Chairpersons: D. Tzanninis, V. Ramfidis

15.15-15.30  **Presenter: J. Duran Moreno**

- **Abstract ID: 11508**
Title: Results of a prospective randomized phase III T-SAR trial comparing trabectedin (T) vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS): A French Sarcoma Group (FSG) trial

15.30-15.45  **Presenter: I. Alafis**

- **Abstract ID: 11507**
Title: Randomized phase II trial of trofosfamide vs. Adriamycin in elderly patients with previously untreated metastatic soft tissue sarcoma

15.45-16.05  **Discussant: S. Kokkali**

16.05-16.15  **Discussion**

16.15-16.30  **Coffee Break**

16.30-17.30  **Session 11: Gynecological Cancer**
Chairpersons: E. Terzakis, D. Trafalis

16.30-16.45  **Presenter: S. Stamatopoulou**

- **Abstract ID: 5500**
Title: Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602

- **Abstract ID: 5505**
Title: Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade leiomyosarcoma: A phase III GOG study

16.45-17.00  **Presenter: I. Syrios**

- **Abstract ID: 5506**
Title: Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17

- **Abstract ID: 5508**
Title: Cost-Effectiveness of Maintenance Therapy in Advanced Ovarian Cancer: Paclitaxel, Bevacizumab, Niraparib, Rucaparib, Olaparib, and Pembrolizumab

17.00-17.20  **Discussant: Ch. Kourousis**

17.20-17.30  **Discussion**

17.30-18.00  **Educational Session: Rational Combinations With an Immuno-Oncology Backbone**
Chairpersons: K. Baxevanis, V. Georgoulias
Presenter: N. Pistalmatzian

18.00-18.20  **General Discussion**

18.20-18.45  **Closing Remarks**